Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Topp, Max S., Gökbuget, Nicola, Zugmaier, Gerhard, Klappers, Petra, Stelljes, Matthias, Neumann, Svenja, Viardot, Andreas, Marks, Reinhard, Diedrich, Helmut, Faul, Christoph, Reichle, Albrecht, Horst, Heinz-August, Brüggemann, Monika, Wessiepe, Dorothea, Holland, Chris, Alekar, Shilpa, Mergen, Noemi, Einsele, Hermann, Hoelzer, Dieter and Bargou, Ralf C. (2014) Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 32 (36), pp. 4134-4140.Date of publication of this fulltext: 19 Dec 2024 08:01
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Journal of Clinical Oncology | ||||
| Publisher: | AMER SOC CLINICAL ONCOLOGY | ||||
|---|---|---|---|---|---|
| Place of Publication: | ALEXANDRIA | ||||
| Volume: | 32 | ||||
| Number of Issue or Book Chapter: | 36 | ||||
| Page Range: | pp. 4134-4140 | ||||
| Date | 2014 | ||||
| Institutions | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
| Identification Number |
| ||||
| Keywords | ACUTE LYMPHOCYTIC-LEUKEMIA; ANTIBODY BLINATUMOMAB; INOTUZUMAB OZOGAMICIN; FREE SURVIVAL; LINEAGE; TRANSPLANTATION; CHEMOTHERAPY; PROGNOSIS; FAILURE; SALVAGE; | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 60888 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric